JP5479346B2 - ピリミジン置換プリン誘導体 - Google Patents

ピリミジン置換プリン誘導体 Download PDF

Info

Publication number
JP5479346B2
JP5479346B2 JP2010527915A JP2010527915A JP5479346B2 JP 5479346 B2 JP5479346 B2 JP 5479346B2 JP 2010527915 A JP2010527915 A JP 2010527915A JP 2010527915 A JP2010527915 A JP 2010527915A JP 5479346 B2 JP5479346 B2 JP 5479346B2
Authority
JP
Japan
Prior art keywords
group
optionally substituted
substituted
alkyl
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010527915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540625A (ja
JP2010540625A5 (enExample
Inventor
ナガラジ，ハリシュ・クマー・マイソール
ウィリアムズ，メレディス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of JP2010540625A publication Critical patent/JP2010540625A/ja
Publication of JP2010540625A5 publication Critical patent/JP2010540625A5/ja
Application granted granted Critical
Publication of JP5479346B2 publication Critical patent/JP5479346B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2010527915A 2007-10-05 2008-10-03 ピリミジン置換プリン誘導体 Expired - Fee Related JP5479346B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97772007P 2007-10-05 2007-10-05
US60/977,720 2007-10-05
US7553208P 2008-06-25 2008-06-25
US61/075,532 2008-06-25
PCT/SG2008/000379 WO2009045175A1 (en) 2007-10-05 2008-10-03 Pyrimidine substituted purine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013253369A Division JP5885729B2 (ja) 2007-10-05 2013-12-06 ピリミジン置換プリン誘導体

Publications (3)

Publication Number Publication Date
JP2010540625A JP2010540625A (ja) 2010-12-24
JP2010540625A5 JP2010540625A5 (enExample) 2011-12-01
JP5479346B2 true JP5479346B2 (ja) 2014-04-23

Family

ID=40030252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010527915A Expired - Fee Related JP5479346B2 (ja) 2007-10-05 2008-10-03 ピリミジン置換プリン誘導体
JP2013253369A Expired - Fee Related JP5885729B2 (ja) 2007-10-05 2013-12-06 ピリミジン置換プリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013253369A Expired - Fee Related JP5885729B2 (ja) 2007-10-05 2013-12-06 ピリミジン置換プリン誘導体

Country Status (16)

Country Link
US (3) US8247410B2 (enExample)
EP (1) EP2209786B1 (enExample)
JP (2) JP5479346B2 (enExample)
KR (3) KR20160116045A (enExample)
CN (2) CN104119336B (enExample)
AU (1) AU2008307798B2 (enExample)
BR (1) BRPI0817503B8 (enExample)
CA (1) CA2701581C (enExample)
DK (1) DK2209786T3 (enExample)
ES (1) ES2406129T3 (enExample)
IL (2) IL204804A (enExample)
MX (1) MX2010003668A (enExample)
MY (1) MY150993A (enExample)
RU (2) RU2681081C2 (enExample)
WO (1) WO2009045175A1 (enExample)
ZA (1) ZA201003118B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
JP5479346B2 (ja) 2007-10-05 2014-04-23 ベラステム・インコーポレーテッド ピリミジン置換プリン誘導体
MX340204B (es) 2008-04-11 2016-06-30 Emergent Product Dev Seattle Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
WO2010005558A2 (en) * 2008-07-07 2010-01-14 Xcovery, Inc. Pi3k isoform selective inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
KR20110098908A (ko) * 2008-11-11 2011-09-02 엑스커버리 홀딩 컴퍼니 엘엘씨 ＰＩ3Ｋ/ｍＴＯＲ 키나제 억제제
EP2411387B1 (en) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CA2757485C (en) 2009-04-03 2017-01-17 Dizhong Chen Pyrimidine substituted purine compounds as kinase (s) inhibitors
WO2010114494A1 (en) * 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
TW201105662A (en) 2009-07-07 2011-02-16 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011078795A1 (en) * 2009-12-21 2011-06-30 S*Bio Pte Ltd Bridged morpholino substituted purines
ES2685171T3 (es) 2010-06-14 2018-10-05 The Scripps Research Institute Reprogramación de células a un nuevo destino
EP2691384B1 (en) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2012172043A1 (en) 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
CA2857601A1 (en) * 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
TW201410657A (zh) 2012-08-02 2014-03-16 Endo Pharmaceuticals Inc 經取代胺基－嘧啶衍生物
KR101982912B1 (ko) * 2013-10-16 2019-09-10 상하이 잉리 파마슈티컬 컴퍼니 리미티드 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2713196T3 (es) 2013-12-11 2019-05-20 Biogen Ma Inc Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
PT3080103T (pt) * 2013-12-11 2018-07-23 Sunesis Pharmaceuticals Inc Compostos de biaril úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
WO2016109426A1 (en) * 2014-12-29 2016-07-07 Verastem, Inc. Oral dosing regimen of a dual mtor and pi3 inhibitor
CN105985354B (zh) * 2015-02-09 2020-10-02 南京盖特医药技术有限公司 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
HRP20190998T1 (hr) 2015-03-30 2019-10-18 Daiichi Sankyo Company, Limited 6-morfolinil-2-pirazolil-9h-purinski derivati i njihova primjena kao p13k inhibitora
KR101589900B1 (ko) 2015-07-30 2016-01-29 강영만 바닥설치용 경계구
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
CN109476696B (zh) * 2016-06-02 2022-06-10 细胞基因公司 动物及人抗锥虫和抗利什曼原虫剂
CN109311843B (zh) * 2016-06-16 2021-10-08 詹森药业有限公司 作为PI3Kβ抑制剂的氮杂苯并咪唑衍生物
ES2911522T3 (es) 2016-12-02 2022-05-19 Daiichi Sankyo Co Ltd Novedosa endo-ß-n-acetilglucosaminidasa
WO2018178944A1 (en) * 2017-03-31 2018-10-04 Ftg Bio Llc Salt forms of amino pyrazine purine based selective kinase inhibitor
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
CN110996959A (zh) 2017-05-23 2020-04-10 梅制药公司 联合疗法
EP3668507A4 (en) 2017-08-14 2021-05-12 MEI Pharma, Inc. Combination therapy
CA3114260A1 (en) * 2018-09-27 2020-04-02 Shanghai Yingli Pharmaceutical Co., Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
MX2021007179A (es) 2018-12-20 2021-09-28 Ksq Therapeutics Inc Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1).
JP2023548148A (ja) 2020-10-30 2023-11-15 ケーエスキュー セラピューティクス， インコーポレイテッド 置換ピラゾロピリミジンの固体形態及びその使用
WO2024041519A1 (zh) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 一种吗啉基喹唑啉类化合物、其药物组合物及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617304A (en) * 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
US4772606A (en) * 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
DE122010000024I1 (de) * 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
TW589309B (en) 1997-07-03 2004-06-01 Bristol Myers Squibb Pharma Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
NZ506234A (en) * 1998-02-26 2003-05-30 Aventis Pharma Inc 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines, pharmaceuticals thereof and their use for inhibiting cdk-2
ES2360933T3 (es) * 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
CN100413852C (zh) * 2000-07-19 2008-08-27 诺瓦提斯公司 缬沙坦的盐
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
CA2502356A1 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
ES2412273T3 (es) * 2002-11-21 2013-07-10 Novartis Ag Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
CN1735607B (zh) * 2002-11-21 2010-06-09 诺华疫苗和诊断公司 2,4,6-三取代的嘧啶作为磷脂酰肌醇(pi)3-激酶抑制剂及其在治疗癌症中的应用
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
JP5321061B2 (ja) 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
GB0519245D0 (en) 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
JP5479346B2 (ja) 2007-10-05 2014-04-23 ベラステム・インコーポレーテッド ピリミジン置換プリン誘導体
WO2009045174A1 (en) * 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
TW200938201A (en) 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
AU2009251291B2 (en) * 2008-05-30 2013-05-02 F. Hoffmann-La Roche Ag Purine PI3K inhibitor compounds and methods of use
WO2009157880A1 (en) * 2008-06-27 2009-12-30 S*Bio Pte Ltd Pyrazine substituted purines
WO2010005558A2 (en) 2008-07-07 2010-01-14 Xcovery, Inc. Pi3k isoform selective inhibitors
CA2757485C (en) 2009-04-03 2017-01-17 Dizhong Chen Pyrimidine substituted purine compounds as kinase (s) inhibitors
WO2010114494A1 (en) 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders

Also Published As

Publication number Publication date
ZA201003118B (en) 2011-08-31
CA2701581A1 (en) 2009-04-09
CN101889015A (zh) 2010-11-17
AU2008307798A1 (en) 2009-04-09
HK1145832A1 (en) 2011-05-06
AU2008307798B2 (en) 2013-10-03
HK1203488A1 (en) 2015-10-30
BRPI0817503A2 (pt) 2015-05-05
MY150993A (en) 2014-03-31
KR101643237B1 (ko) 2016-07-27
KR20150063171A (ko) 2015-06-08
CA2701581C (en) 2016-12-20
KR20160116045A (ko) 2016-10-06
CN104119336B (zh) 2016-08-24
JP5885729B2 (ja) 2016-03-15
BRPI0817503B8 (pt) 2021-05-25
RU2518098C2 (ru) 2014-06-10
US20140066620A1 (en) 2014-03-06
JP2010540625A (ja) 2010-12-24
US8609838B2 (en) 2013-12-17
CN104119336A (zh) 2014-10-29
BRPI0817503B1 (pt) 2019-10-29
DK2209786T3 (da) 2013-06-03
IL235555A0 (en) 2014-12-31
US20100298319A1 (en) 2010-11-25
RU2681081C2 (ru) 2019-03-04
IL204804A0 (en) 2010-11-30
US20130079512A1 (en) 2013-03-28
EP2209786A1 (en) 2010-07-28
RU2010117737A (ru) 2011-11-10
CN101889015B (zh) 2014-06-04
KR20100075609A (ko) 2010-07-02
RU2014110894A (ru) 2015-07-10
IL235555B (en) 2019-08-29
WO2009045175A1 (en) 2009-04-09
JP2014139159A (ja) 2014-07-31
US8247410B2 (en) 2012-08-21
MX2010003668A (es) 2010-07-02
KR101701109B1 (ko) 2017-02-13
EP2209786B1 (en) 2013-02-27
IL204804A (en) 2014-11-30
ES2406129T3 (es) 2013-06-05

Similar Documents

Publication Publication Date Title
JP5885729B2 (ja) ピリミジン置換プリン誘導体
US20110009403A1 (en) 2-morpholinylpurines as inhibitors of pi3k
US20110105500A1 (en) Pyrazine substituted purines
WO2010114494A1 (en) 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
US9138437B2 (en) Pyrimidine substituted purine compounds as kinase (S) inhibitors
WO2009093981A1 (en) Triazine compounds as kinase inhibitors
WO2011078795A1 (en) Bridged morpholino substituted purines
AU2013251254B2 (en) Pyrimidine substituted purine derivatives
HK1145832B (en) Pyrimidine substituted purine derivatives
HK1203488B (en) Pyrimidine substituted purine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111003

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111003

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20121227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140212

R150 Certificate of patent or registration of utility model

Ref document number: 5479346

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees